Risk of drug-related mortality among people receiving opioid-agonist treatment during the Covid-19 pandemic in Scotland
Bibliographic Data
| ID | 14905758 |
|---|---|
| Authors | Megan Glancy (0000-0003-2023-9353, Glasgow Caledonian University, corresponding author), Andrew Mcauley (0000-0002-6047-2400, Glasgow Caledonian University), Norah Palmateer, Norah E Palmateer (0000-0003-4493-0173, Glasgow Caledonian University), Kirsten Trayner, Kirsten M A Trayner (0000-0002-4442-3510, Glasgow Caledonian University), Alan Yeung (0000-0001-5226-3695, Glasgow Caledonian University), Lee Barnsdale (0009-0000-1962-951X, Public Health Scotland), Saket Priyadarshi (0009-0002-1229-4838, NHS Greater Glasgow and Clyde), Kirsten Horsburgh, Matthew Hickman (0000-0001-9864-459X, University of Bristol), Sharon Hutchinson (0000-0002-6891-6758, Glasgow Caledonian University) |
| Year | 2025 |
| Volume | 143 |
| Pages | 104912 |
| Publication date | 2025-09-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | International Journal of Drug Policy (JOURNAL) |
| Journal identifiers | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2025.104912 |
| PMID | 40618656 |
| OpenAlex | W4412060259 |
| Language | EN |
| Citations received | 1 |
| References cited | 46 |
During the COVID-19 pandemic in Scotland, DRD rates remained stable following a three-fold rise since 2011-13. The protective effect of OAT was sustained during the pandemic, which highlights the importance of maintaining access to OAT during public health crises
2019-20 coronavirus outbreak · Agonist · Buprenorphine · Coronavirus disease 2019 (COVID-19 · Drug · Infectious disease (medical specialty · Opioid · Pandemic · Psychiatry · Receptor · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 · Cardiac Arrest and Resuscitation · HIV, Drug Use, Sexual Risk · Medicine · Opioid Use Disorder Treatment · Psychology · Emergency Medicine · Internal Medicine · Virology
Challenges posed by Covid‐19 to people who inject drugs and lessons from other outbreaks
Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence
Trends in deaths following drug use in England before, during, and after the Covid-19 lockdowns
The impact of Covid-19 on access to harm reduction, substance use treatment and recovery services in Scotland
Living Under Coronavirus and Injecting Drugs in Bristol (Lucid-B)
Barriers to engaging people who use drugs in harm reduction services during the Covid-19 pandemic
Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey
High levels of all-cause mortality among people who inject drugs from 2018 to 2022
A rapid review of the impacts of “Big Events ” on risks, harms, and service delivery among people who use drugs
National increase in the community supply of take‐home naloxone associated with a mass media campaign in Scotland
From the clinic to the street
Sars-CoV-2 vaccine uptake and risks of severe Covid-19 disease among people prescribed opioid agonist therapy in Scotland
| Unique citing works | 1 |
|---|---|
| Citations per year | 1 |
| Citation span | 2026 - 2026 (1) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 1 |